Ravneesh Sachdev is a partner and head of business development at ATP with more than 20 years of experience inorganically creating value for large and mid-sized biopharma companies. Most recently, Ravneesh was senior vice president and head of business development at Acceleron Pharma, a commercial-stage biopharma company focused on therapeutics treating rare hematologic and pulmonary diseases, where he established Acceleron’s partnering strategy before eventually leading the company’s sale to Merck for $11.5 billion. Prior to Acceleron, Ravneesh was at Sage Therapeutics in a similar leadership role that culminated in a $3.2 billion strategic collaboration with Biogen. Over his career, he has both led and contributed to the execution of more than 30 transactions at Pfizer, Onyx Pharmaceuticals (including the company sale to Amgen for $10.4 billion), UCB Pharma, Acorda Therapeutics and Bioverativ (including the company sale to Sanofi for $11.6 billion).
Ravneesh earned his bachelor’s degree in molecular neuroscience from Claremont McKenna College, his Master of Business and Science degree from the Keck Graduate Institute, and his MBA in healthcare leadership from Yale University School of Management.
Celebrating 25 years of innovation! 25.kgi.edu.